Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Department Of Health And Human Services was posted on May 15, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

A--Mouse Models for Down Syndrome

Closed
75N94026R00006Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Grant
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)This contract opportunity from the National Institutes of Health under the Department of Health and Human Services aims to support the development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment. It focuses on accelerating early-stage therapeutic candidates through preclinical optimization to readiness for Phase II clinical trials. Eligible applicants must present a promising lead candidate with strong biological justification and established assays to guide optimization. The funded activities include lead optimization, early development, IND-enabling studies, biomarker development, submission of an Investigational New Drug application, and Phase I clinical testing. The program is structured as a milestone-driven, phased cooperative agreement with active NIH involvement in project planning and monitoring. The solicitation is identified as RFA-NS-27-007, titled HEAL Initiative: Non-addictive Analgesic Therapeutics Development, with clinical trials optional. The solicitation was posted on June 16, 2026, and applicants must respond by February 20, 2029. This federal contract emphasizes collaborative advancement of innovative pain therapeutics while ensuring rigorous oversight from NIH program staff throughout the project lifecycle.
National Institutes Of Health

POSTED

about 21 hours ago

DEADLINE

in over 2 years
NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The National Institutes of Health, specifically the NICHD under the Department of Health and Human Services, intends to issue a solicitation for a contract focused on the maintenance and distribution of mouse models used in Down syndrome research. This effort involves breeding, acquiring, and managing specific mouse strains while ensuring pathogen-free colonies to support scientific studies. The contract is planned as a cost-reimbursement agreement with an initial one-year base period and four possible one-year extensions, indicating a long-term commitment to supporting this area of biomedical research. The solicitation, identified as 75N94026R00006 and posted in late April 2026, targets capable small businesses experienced in research and development related to animal model management. The project also includes convening a scientific advisory board to provide guidance and oversight. The location associated with this contract is Bethesda, Maryland, reflecting NIH’s operational base. Interested parties must submit capability statements or responses by late May 2026 to be considered for this opportunity. The focus on specialized mouse models highlights the NIH’s strategic investment in advancing Down syndrome research through high-quality, well-maintained biological resources.

General Info

NIH seeks small businesses for managing pathogen-free Down syndrome mouse models; five-year contract.

Agency

Department Of Health And Human Services → National Institutes Of Health Nichd

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

MD

Set-Aside

NONE

Documents

(9)

Sol_75N94026R00006.pdf

PDF

Sources Sought Notice 75N94026R00006 Repository of Mouse Models for Down Syndrome

PDF5 pagessources-sought

Sol_75N94026R00006_Amd_0002.pdf

PDF

RFP_75N94026R00006.pdf

PDF

Sol_75N94026R00006_Amd_0003.pdf

PDF

RFP_75N94026R00006_Amendment_0003_-_Attachment_1_0003.pdf

PDF

Pre-Solicitation Notice for Repository of Mouse Models for Down Syndrome

PDFpresolicitation

RFP_75N94026R00006_Amendment_0002_-_Attachment_1_0002.pdf

PDF

Sol_75N94026R00006_Amd_0001.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

3 updates
PhaseClosed
Type Changed

Presolicitation → Solicitation

Amendment 3

Contract was updated

Amendment 4

Contract was updated

Posted

Presolicitation

Amendment 5

Contract was updated

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Nichd
Contacts1 person available
OfficeBETHESDA, MD, 20817, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Nichd
Office AddressBETHESDA, MD, 20817, USA

Full Description

Show more
Repository of Mouse Model for Down Syndrome Research.